Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
18 mars 2025 08h02 HE
|
Ocugen
OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18,...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
05 mars 2025 07h02 HE
|
Ocugen
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in...
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
03 mars 2025 09h00 HE
|
Ocugen
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
27 févr. 2025 08h46 HE
|
Ocugen
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
21 févr. 2025 08h00 HE
|
Ocugen
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
12 févr. 2025 07h42 HE
|
Ocugen
Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse...
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
03 févr. 2025 06h30 HE
|
Ocugen
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
27 janv. 2025 06h30 HE
|
Ocugen
OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
16 janv. 2025 07h30 HE
|
Ocugen
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
13 janv. 2025 06h30 HE
|
Ocugen
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects...